Showing results (201-210 of 679) with videos related to

Sort By:
Pageof 68
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panelBruce D Cheson, Clemens-Martin Wendtner, Angelika Pieper, et al.
Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 6, 2009
Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?Pierre Y Salaun, Thomas Gastinne, Caroline Bodet-Milin, et al.
Blood Cancer Journal|March 11, 2020
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysisMeletios A Dimopoulos, Ruben Niesvizky, Katja Weisel, et al.
Leukemia & Lymphoma|May 14, 2016
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)Philippe Moreau, Katja C Weisel, Kevin W Song, et al.
Cell Death & Disease|May 7, 2020
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexesCarolane Seiller, Sophie Maiga, Cyrille Touzeau, et al.
Cancers|September 9, 2020
Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III TrialsAnne-Victoire Michaud-Robert, Elena Zamagni, Thomas Carlier, et al.
International Journal of Molecular Sciences|February 21, 2017
PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma PatientsClément Bailly, Rodolphe Leforestier, Bastien Jamet, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 3, 2012
Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patientsOlivier Decaux, Alain Renault, Véronique Sébille, et al.
Leukemia|June 12, 2019
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myelomaSophia Adamia, Ivane Abiatari, Samir B Amin, et al.
Pageof 68